• <menu id="888u4"><menu id="888u4"></menu></menu>
  • Production of Zirconium-89 and the Development of Zr-89 Radiopharmaceuticals

    Closed for proposals

    Project Type

    Coordinated Research Project

    Project Code

    F22071

    CRP

    2223

    Approved Date

    4 December 2018

    Status

    Active - Ongoing

    Start Date

    3 December 2019

    Expected End Date

    31 December 2024

    Participating Countries

    Canada
    China
    France
    Germany
    India
    Iran (Islamic Republic of)
    Italy
    Japan
    Poland
    Portugal
    Republic of Korea
    Romania
    Saudi Arabia
    South Africa
    United Kingdom of Great Britain and Northern Ireland
    United States of America

    Description

    Positron Emission Tomography (PET) technique is an exciting tool in nuclear medicine capable of imaging biological processes up to subcellular concentrations at molecular level. Although the short half-life PET radiopharmaceuticals have been available for more than 3 decades, tracing and quantification of slow biological processes and molecules with longer biological half-lives have only been recently possible using PET tracers with longer half-lives including I-124 and Zr-89. Among those, Zr-89 has attracted higher value especially in the pharmacokinetics studies and clinical evaluation of monoclonal antibodies (mAbs) and large proteins due to attractive physicochemical properties. This Coordinated Research Project (CRP) will identify new technical aspects of the targetry, production and quality control of Zr-89 radioisotope and related radiopharmaceuticals with slow pharmacokinetics especially mAbs.

    Objectives

    Formulate guidelines to enhance and strengthen the expertise and capability of Member States in production (targetry, separation) and quality control of Zr-89 radioisotope as well as covering all aspects of Zr-89 radiopharmaceuticals development.

    Specific objectives

    Producing guidelines for the production of Zr-89 radioisotope using medical cyclotrons through the 89Y(p,n)89Zr and the optimization of:
    -Available targetry methods (solid and liquid targets)
    -Available separation & purification methods
    -Quality control protocols of radioisotope produced

    Producing guidelines for preparation, evaluation and quality control of Zr-89 labelled molecules with focus on developing Zr-89 radiopharmaceuticals including:
    -Biomolecule conjugation
    -Radiolabeling & characterization, Stability studies
    Quality control
    In-vitro specificity evaluation (such as Immunoreactivity, receptor binding, cell kinetic studies etc.)
    -Preclinical studies in laboratory animal models -etc.

    Contact the project officer

    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Image CAPTCHA

    Stay in touch

    Newsletter

    午夜爱爱爱爱爽爽爽视频网站